RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.
Missing: RevDia's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: RevDia's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing RevDia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
RevDia is included in 2 Expert Collections, including Diabetes.
Health Monitoring & Diagnostics
Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting
RevDia Frequently Asked Questions (FAQ)
Where is RevDia's headquarters?
RevDia's headquarters is located at 601 West 20th Street, Hialeah.
What is RevDia's latest funding round?
RevDia's latest funding round is Series C.
Who are the investors of RevDia?
Investors of RevDia include Emergent Growth Fund and University of Florida.
Who are RevDia's competitors?
Competitors of RevDia include Elusys Therapeutics, Fujirebio, NGM Biopharmaceuticals, DiaMedica, BioMarck Pharmaceuticals and 16 more.
Compare RevDia to Competitors
CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.
Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.
Tyrian Diagnostics is a biotechnology company that specialises in the discovery of biomarkers of disease and in diagnostic test development. The company are building a strong intellectual property portfolio to develop a pipeline of diagnostic products and establishing commercial partnerships to maximise market share and revenue generation from these products. One key avenue for commercialisation is the application of biomarkers to the company's point of need test platform, DiagnostIQTM.
CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.
Afraxis discover and develops drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. Afraxis is leveraging this discovery to develop drug treatments that control dendritic spine function. The company's lead program targets PAK, a protein that regulates the development and activity of dendritic spines, creating therapies that actually modify the disease rather than just treat symptoms. Modifying the disease produces beneficial changes at the cellular and behavioral level, creating new hope for patients.
Acologix strives to improve patients' lives by developing and commercializing biopharmaceuticals targeting "osteo-renal"(bone and kidney) diseases. Acologix's deep expertise in mineral metabolism sciences is the key to solving major osteo-renal health problems. Periodontal disease, oral care, orthopedics, osteoporosis, chronic kidney disease and its secondary complications such as renal osteodystrophy and uremic pruritus represent underserved medical needs. Acologix is in its focus on these rapidly growing health care problems.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.